Gilead Sciences (GILD) Revenue — Quarter Ended Mar 31, 2023
Revenue declined in the quarter. The decrease was observed both sequentially and compared to the same quarter a year earlier.
Key takeaway
Quarter ended Mar 31, 2023 · FY2023 Q1
Revenue declined in the quarter. The decrease was observed both sequentially and compared to the same quarter a year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$6.4B
Revenue reported for this quarter.
Quarter-over-quarter
-14.0%
Change from the immediately preceding quarter.
Year-over-year
-3.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$27B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2022 | $6.3B | +0.7% |
| Sep 30, 2022 | $7B | -5.1% |
| Dec 31, 2022 | $7.4B | +2.0% |
| Mar 31, 2023 | $6.4B | -3.6% |
Revenue performance
The reported revenue fell from the immediately preceding quarter, reversing the prior quarter's growth. The sequential decline was notable.
Quarterly comparison
Compared to the same quarter one year ago, revenue also decreased. The trailing twelve-month revenue remained substantial despite the drop.
What to watch
Cash and cash equivalents decreased from the end of the prior fiscal year, and operating cash flow was lower than the same period last year.